Key Takeaways
- • Global venture funding surged to $297–$300 billion in Q1 2026, up 150% quarter-over-quarter and year-over-year, representing an all-time record and nearly 70% of total 2025 venture capital deployment in a single quarter.
- • Artificial intelligence companies captured 80–81% of all global venture funding ($239–$242 billion), with four mega-rounds—OpenAI ($122 billion at $852 billion valuation), Anthropic ($30 billion), xAI ($20 billion), and Waymo ($16 billion)—collectively accounting for 64–65% of quarterly venture investment.
- • Mega-rounds of $100 million or larger represented 86% of all venture dollars deployed, signaling extreme capital concentration; mega-deals accounted for approximately 70% of U.S. venture funding in the quarter, creating a bifurcated market favoring AI frontier labs and select high-profile companies.
- • Digital health startups raised $4 billion in Q1 2026, up $1 billion year-over-year and the strongest first quarter since the pandemic peak, with 12 mega-deals capturing 59% of total digital health funding and average deal size reaching $36.7 million—the highest since Q4 2021.
- • OpenAI's record $122 billion raise included participation from Amazon, Nvidia, and SoftBank; the company reported $2 billion in monthly revenue, 900 million weekly active users, and expects enterprise clients to represent 50% of revenue by year-end, with retail investors contributing over $3 billion for the first time.
Summary
Q1 2026 marked a historic inflection point for venture capital, with global investment reaching $297–$300 billion—a threshold that shatters all previous quarterly records and represents growth of 150% from both the prior quarter and the same period in 2025. According to Crunchbase data, this single quarter accounted for nearly 70% of all venture capital deployed throughout 2025 and exceeded the total venture investment for any full year prior to 2018. The magnitude of this surge reflects unprecedented investor appetite for artificial intelligence infrastructure and frontier models.
The extraordinary capital concentration underscores the dominance of AI in the venture ecosystem. Artificial intelligence companies captured 80–81% of global venture funding in Q1, totaling $239–$242 billion—a dramatic increase from 55% in Q1 2025. Four mega-rounds closed in the quarter that rank among the five largest venture rounds ever recorded: OpenAI secured $122 billion at an $852 billion valuation, anchored by Amazon, Nvidia, and SoftBank with Microsoft remaining a strategic partner; Anthropic raised $30 billion; xAI raised $20 billion; and autonomous vehicle company Waymo raised $16 billion. These four deals collectively generated $188 billion, representing 64–65% of all Q1 venture investment. OpenAI's round marked the first instance of retail investor participation in such a mega-round, with over $3 billion contributed through bank channels. The company now generates $2 billion in monthly revenue, boasts 900 million weekly active users, and expects enterprise clients to comprise 50% of revenue by year-end.
Capital concentration has intensified dramatically, with mega-rounds of $100 million or larger accounting for 86% of all venture dollars globally, almost entirely within the AI sector. In the United States specifically, mega-deals represented approximately 70% of venture funding, creating a bifurcated market in which a select group of AI firms raise vast sums while the broader startup ecosystem faces materially tighter funding conditions.
Beyond frontier AI labs, digital health startups demonstrated resilience, raising $4 billion in Q1 2026—up $1 billion year-over-year and marking the strongest first quarter since the pandemic peak. However, the concentration dynamic visible in AI also applies to digital health: just 12 mega-deals (each $100 million or larger) captured 59% of total quarterly funding. Notable rounds included Whoop's $575 million Series G, OpenEvidence's $250 million Series D, Verily's $300 million funding, telepsychiatry provider Talkiatry's $210 million Series D, and eMed's $200 million Series A. Average deal size in digital health climbed to $36.7 million, the highest quarterly average tracked since Q4 2021. The prevalence of AI-enabled solutions among top-funded digital health companies reflects AI's emergence as table stakes for capital deployment across healthcare venture investing.
The extraordinary capital concentration underscores the dominance of AI in the venture ecosystem. Artificial intelligence companies captured 80–81% of global venture funding in Q1, totaling $239–$242 billion—a dramatic increase from 55% in Q1 2025. Four mega-rounds closed in the quarter that rank among the five largest venture rounds ever recorded: OpenAI secured $122 billion at an $852 billion valuation, anchored by Amazon, Nvidia, and SoftBank with Microsoft remaining a strategic partner; Anthropic raised $30 billion; xAI raised $20 billion; and autonomous vehicle company Waymo raised $16 billion. These four deals collectively generated $188 billion, representing 64–65% of all Q1 venture investment. OpenAI's round marked the first instance of retail investor participation in such a mega-round, with over $3 billion contributed through bank channels. The company now generates $2 billion in monthly revenue, boasts 900 million weekly active users, and expects enterprise clients to comprise 50% of revenue by year-end.
Capital concentration has intensified dramatically, with mega-rounds of $100 million or larger accounting for 86% of all venture dollars globally, almost entirely within the AI sector. In the United States specifically, mega-deals represented approximately 70% of venture funding, creating a bifurcated market in which a select group of AI firms raise vast sums while the broader startup ecosystem faces materially tighter funding conditions.
Beyond frontier AI labs, digital health startups demonstrated resilience, raising $4 billion in Q1 2026—up $1 billion year-over-year and marking the strongest first quarter since the pandemic peak. However, the concentration dynamic visible in AI also applies to digital health: just 12 mega-deals (each $100 million or larger) captured 59% of total quarterly funding. Notable rounds included Whoop's $575 million Series G, OpenEvidence's $250 million Series D, Verily's $300 million funding, telepsychiatry provider Talkiatry's $210 million Series D, and eMed's $200 million Series A. Average deal size in digital health climbed to $36.7 million, the highest quarterly average tracked since Q4 2021. The prevalence of AI-enabled solutions among top-funded digital health companies reflects AI's emergence as table stakes for capital deployment across healthcare venture investing.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.